Sarcoidosis Study

Study Summary

The University of Chicago and Dr. Nadera Sweiss are conducting a study for individuals who suffer from sarcoidosis. It is a rare disease that can affect any organ in the body and it is characterized by the build-up of immune-system (fights off infection in the body) cells in organs. These cells form small groups called granulomas, which lead to inflammation of the surrounding tissue. Sarcoidosis most commonly affects the lung and the lymph nodes (part of the immune system). The signs usually include shortness of breath, fever, dry cough and chest pain. Other signs in many patients can include redness and painful lumps on the skin, reduced eyesight, joint pain, and rarely, nervous system damage. Sarcoidosis commonly affects young and middle-aged adults.

This study involves an experimental drug. The purpose of this study is to evaluate the safety and effectiveness of adalimumab for patients with sarcoidosis with pulmonary (lung) involvement who show symptoms of the disease even though they are currently being treated with medication.

There are no approved therapies for the treatment of sarcoidosis. Corticosteroid (steroid hormone) therapy is considered the standard treatment. Only limited benefit has been shown when using corticosteroid therapy to ease lung symptoms or improve lung function in patients with sarcoidosis.

The length of your participation in this study is approximately 54 weeks and will include approximately 11 clinic visits.

There may be no direct benefit to you for participating in this study. However, the possible findings of this study may lead to improved treatments for patients who have rheumatoid arthritis.

Participation Details

• You must be 18 or older
• You must be diagnosed with Sarcoidosis at least 1 year prior to screening
• You must be willing and able to adhere to the study visit schedule and other protocol-specified procedures
• You must be available for clinic visits for the duration of the study
• You must meet study medical criteria as evaluated by Dr. Sweiss

Study Director: Dr. Nadera Sweiss
Department: Rheumatology

For more information contact:
Misel Ramirez
mramirez@medicine.bsd.uchicago.edu
(773) 702 2645

IRB: #14093A